Research programme: decoy oligonucleotide therapies - Onxeo

Drug Profile

Research programme: decoy oligonucleotide therapies - Onxeo

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Onxeo SA
  • Class Antineoplastics; Oligonucleotides; Small molecules
  • Mechanism of Action DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Oct 2017 Onxeo plans preclinical studies for the first candidate from the programme in the first half of 2018
  • 27 Jun 2017 Onxeo receives patent protection for platON™ platform of decoy oligonucleotides and its potential applications in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top